European Firms May Shift Away From China Due To Tougher Environment – European Chamber Of Commerce Survey
This article was originally published in PharmAsia News
Survey finds lingering challenges and uncertainty despite – and sometimes because – of new government measures.
You may also be interested in...
HONG KONG - Rising labor costs are putting stress on manufacturing operations in China, but may prove to be a boon in the long term for companies focused on the world's fastest-growing domestic market
CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.